Life Sciences»Pharmaceuticals»Drug Discovery
Chikungunya - Pipeline Review, H2 2015
| Lowest Prices Guaranteed | Length | Publisher | Published Date | SKU |
|---|---|---|---|---|
| from $2,000 | 87 Pages | Global Markets Direct | October, 2015 | GMD5792326 |
| Lowest Prices Guaranteed | |
| Price | from $2,000 |
|---|---|
| Length | 87 Pages |
| Publisher | Global Markets Direct |
| Published Date | October, 2015 |
| SKU | GMD5792326 |
Table of Contents
Chikungunya - Pipeline Review, H2 2015
Global Markets Direct
- Introduction
- Global Markets Direct Report Coverage
- Chikungunya Overview
- Therapeutics Development
- Pipeline Products for Chikungunya - Overview
- Pipeline Products for Chikungunya - Comparative Analysis
- Chikungunya - Therapeutics under Development by Companies
- Chikungunya - Therapeutics under Investigation by Universities/Institutes
- Chikungunya - Pipeline Products Glance
- Clinical Stage Products
- Early Stage Products
- Unknown Stage Products
- Chikungunya - Products under Development by Companies
- Chikungunya - Products under Investigation by Universities/Institutes
- Chikungunya - Companies Involved in Therapeutics Development
- Abivax S.A.
- Arbovax, Inc.
- Arno Therapeutics, Inc.
- Bharat Biotech International Limited
- Etubics Corporation
- Indian Immunologicals Limited
- Inovio Pharmaceuticals, Inc.
- Integral Molecular, Inc.
- Merck & Co., Inc.
- Nanotherapeutics, Inc.
- PaxVax
- Profectus BioSciences, Inc.
- Takeda Pharmaceutical Company Limited
- Themis Bioscience GmbH
- Chikungunya - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- ABX-309 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Antibody for Chikungunya - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AR-12 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- chikungunya vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- chikungunya vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- chikungunya vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- chikungunya vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- chikungunya vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- chikungunya vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- chikungunya vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- chikungunya vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- chikungunya vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- chikungunya vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- chikungunya vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- chikungunya vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- chikungunya vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- chikungunya vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- chikungunya vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- chikungunya vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- DEF-201 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- IMCKV-063 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Monoclonal Antibodies for Chikungunya - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Monoclonal Antibodies to Inhibit Viral E1/E2 Proteins for Chikungunya - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MV-CHIK - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecule to Inhibit NS2 and NS3 for Chikungunya - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecules to Inhibit Viral RNA for Chikungunya Virus Infections - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Chikungunya - Recent Pipeline Updates
- Chikungunya - Dormant Projects
- Chikungunya - Product Development Milestones
- Featured News & Press Releases
- Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs
- Mar 02, 2015: Themis Bioscience’s Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases
- Dec 10, 2014: Integral Molecular identifies potent inhibitory antibodies against Chikungunya virus
- Nov 20, 2014: Themis Bioscience’s Vaccine Against Chikunguya Successful In Phase 1
- Jun 12, 2014: Threat of Emerging Virus can be Stopped: Interim results of First Clinical Trial of Themis Bioscience's Vaccine Candidate Against Chikungunya Fever Prove Successful
- Mar 27, 2013: Themis Bioscience Plans To Initiate Phase I Study Of Chikungunya Fever Vaccine Candidate
- Aug 15, 2011: Inviragen And University of Texas Medical Branch Receive Funding For Development Of Chikungunya Virus Vaccine
- Nov 04, 2010: Novel Recombinant Chikungunya Virus Vaccine Shown To Be Safe And Effective In Multiple Animal Models
- Nov 02, 2010: Inviragen Receives Two Therapeutic Discovery Project Grants For Vaccine Development
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Chikungunya, H2 2015
- Number of Products under Development for Chikungunya - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Number of Products under Development by Companies, H2 2015 (Contd...1)
- Number of Products under Investigation by Universities/Institutes, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Comparative Analysis by Early Stage Development, H2 2015
- Comparative Analysis by Unknown Stage Development, H2 2015
- Products under Development by Companies, H2 2015
- Products under Development by Companies, H2 2015 (Contd...1)
- Products under Investigation by Universities/Institutes, H2 2015
- Chikungunya - Pipeline by Abivax S.A., H2 2015
- Chikungunya - Pipeline by Arbovax, Inc., H2 2015
- Chikungunya - Pipeline by Arno Therapeutics, Inc., H2 2015
- Chikungunya - Pipeline by Bharat Biotech International Limited, H2 2015
- Chikungunya - Pipeline by Etubics Corporation, H2 2015
- Chikungunya - Pipeline by Indian Immunologicals Limited, H2 2015
- Chikungunya - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015
- Chikungunya - Pipeline by Integral Molecular, Inc., H2 2015
- Chikungunya - Pipeline by Merck & Co., Inc., H2 2015
- Chikungunya - Pipeline by Nanotherapeutics, Inc., H2 2015
- Chikungunya - Pipeline by PaxVax, H2 2015
- Chikungunya - Pipeline by Profectus BioSciences, Inc., H2 2015
- Chikungunya - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
- Chikungunya - Pipeline by Themis Bioscience GmbH, H2 2015
- Assessment by Monotherapy Products, H2 2015
- Number of Products by Stage and Target, H2 2015
- Number of Products by Stage and Mechanism of Action, H2 2015
- Number of Products by Stage and Route of Administration, H2 2015
- Number of Products by Stage and Molecule Type, H2 2015
- Chikungunya Therapeutics - Recent Pipeline Updates, H2 2015
- Chikungunya - Dormant Projects, H2 2015
- List of Figures
- Number of Products under Development for Chikungunya, H2 2015
- Number of Products under Development for Chikungunya - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Number of Products under Investigation by Universities/Institutes, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Comparative Analysis by Early Stage Products, H2 2015
- Assessment by Monotherapy Products, H2 2015
- Number of Products by Top 10 Targets, H2 2015
- Number of Products by Stage and Top 10 Targets, H2 2015
- Number of Products by Top 10 Mechanism of Actions, H2 2015
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
- Number of Products by Routes of Administration, H2 2015
- Number of Products by Stage and Routes of Administration, H2 2015
- Number of Products by Top 10 Molecule Types, H2 2015
- Number of Products by Stage and Top 10 Molecule Types, H2 2015
Description
Chikungunya - Pipeline Review, H2 2015
Global Markets Direct
Chikungunya - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Chikungunya - Pipeline Review, H2 2015’, provides an overview of the Chikungunya’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Chikungunya, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chikungunya and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Chikungunya
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chikungunya and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chikungunya products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chikungunya pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chikungunya
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chikungunya pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Search inside this report
| Online Download | $2,000 | |
|---|---|---|
| Site License | $4,000 | |
| Global Site License | $6,000 |
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBookOther tasks
